| Intrinsic Valuation of: MAXHEALTH | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 11 | Market Cap | ₹1,244B | |||||
| 2021 | - | - (-) | P/E Ratio | 116 | Total Asset | ₹152B | |||||
| 2022 | ₹2B | - (-) | Net Income | ₹11B | Total Debt | ₹23B | |||||
| 2023 | ₹9B | 406.7% (338.4%) | EBITDA | ₹19B | Total Liab | ₹58B | |||||
| 2024 | ₹3B | -64.6% (-70.6%) | Opr Margin | 0.21 | Debt/Equity | 0.24 | |||||
| 2025 | ₹5B | 47.1% (13.1%) | PreTax Margin | 18.84 | BV/Share | 34 | |||||
| 5Y Average FCF | ₹5B | 129.7% (93.6%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (25.0%) | ||||||||||
| 2026 | ₹6B | MBG Intrinsic Value | ₹98 | ||||||||
| 2027 | ₹8B | ||||||||||
| 2028 | ₹10B | ||||||||||
| 2029 | ₹12B | ||||||||||
| 2030 | ₹15B | ||||||||||
| 2031 | ₹19B | ||||||||||
| Terminal Value | ₹392B | Net Worth/Share | ₹96 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹307B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹7B | ₹299 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹23B | WACC | 7.3% | 258 | 280 | 306 | 339 | 380 | |||
| Equity Value | ₹291B | 7.4% | 255 | 277 | 303 | 334 | 374 | ||||
| Shares Outstanding | 972,147,008 | 7.4% | 253 | 274 | 299 | 330 | 369 | ||||
| 7.9% | 230 | 247 | 267 | 292 | 322 | ||||||
| DCF Intrinsic Value | ₹299 | 8.4% | 210 | 224 | 241 | 261 | 285 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||